SCHEMBL26075882

SCHEMBL26075882

Cc1cc(-c2ccc(-c3ccc(OCCC(C)C)cc3)c(F)c2)nc2ccc(P)cc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.39
▸ MCHR1 Q99705 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ DHODH Q02127 1/20 0.33
▸ PLA2G2A P14555 2/20 0.33
▸ CA4 P22748 1/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ ACACA Q13085 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075871 0.90 ALOX5AP (0.39) MAPTTP53GAADHODHALOX5AP
SCHEMBL26075287 0.90 DHODH (0.38) MAPTMCHR1TP53DHODHPLA2G2A
SCHEMBL26075867 0.89 PLA2G2A (0.42) MAPTDHODHPLA2G2APDE10A
SCHEMBL26075866 0.89 DHODH (0.43) DHODHPLA2G2APDE10AACACA
SCHEMBL26075897 0.88 SQOR (0.37) DHODHPLA2G2APDE10AESR1ESR2
SCHEMBL26075877 0.87 PLA2G2A (0.41) MAPTDHODHPLA2G2APDE10A
SCHEMBL26075902 0.87 NCF1 (0.37) DHODHPLA2G2APDE10AESR1ESR2
SCHEMBL26075885 0.87 HMOX1 (0.41) MAPTTP53GAAMAPK1ESR1
SCHEMBL26075373 0.87 HTR2B (0.40) MAPTMCHR1TP53ALOX5APFEN1
SCHEMBL26075880 0.86 PLA2G2A (0.41) MAPTDHODHPLA2G2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD MAPT 2689/4885MCHR1 3681/4885TP53 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback